Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin

Ähnliche Einträge

• Impact of the timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes
  von: Cong Xie, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
  von: Leili Gao, et al.
  Veröffentlicht: (2025)
• Metformin monotherapy versus predominantly older non‐metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management
  von: Mingyang Sun, et al.
  Veröffentlicht: (2024)
• Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials
  von: Weihao Wang, et al.
  Veröffentlicht: (2024)
• Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
  von: Yao Wang, et al.
  Veröffentlicht: (2024)